Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. [electronic resource]
Producer: 20080408Description: 198-208 p. digitalISSN:- 0304-3835
- Animals
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents -- pharmacology
- Bone Marrow -- drug effects
- Breast Neoplasms -- blood
- Cell Line, Tumor
- Chromosomes, Human, X
- Drug Resistance, Neoplasm
- ErbB Receptors -- antagonists & inhibitors
- Female
- Histocompatibility Antigens Class I -- analysis
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Leukocyte Common Antigens -- analysis
- Mice
- Mice, SCID
- Neoplasm Metastasis
- Neoplastic Cells, Circulating -- drug effects
- Rituximab
- Time Factors
- Trastuzumab
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.